Nitrogen Other Than As Nitro Or Nitroso Nonionically Bonded Patents (Class 514/561)
  • Patent number: 10265278
    Abstract: The present invention provides a pharmaceutical composition for oral administration comprising a D-amino acid combined with an antioxidant selected from the group consisting of vitamin E, vitamin C, a glutathione or a precursor thereof.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: April 23, 2019
    Inventor: Daniel Javitt
  • Patent number: 10255497
    Abstract: The invention relates to a method and to a device for authenticating and/or identifying persons, objects, or service systems. In said method, a material, a construction, a substance, or a composition, or an image thereof, either changes itself or is actively changed, by means of a physical, chemical, or mechanical influence or feature, such that the resulting structure or feature is unforeseeable. If an image of said material, of the construction, of the substance, or the composition recorded at a later time is compared with the image stored in a storage means, the person and/or the object and/or the medium and/or service system is positively authenticated if the material, the construction, the substance, or the composition has at least partially changed between the two times in comparison with the image stored in the storage means.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: April 9, 2019
    Inventor: Friedrich Kisters
  • Patent number: 10241093
    Abstract: The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: March 26, 2019
    Assignee: The Cleveland Clinic Foundation
    Inventors: Stanley L. Hazen, Zeneng Wang, Bruce S. Levison
  • Patent number: 10188635
    Abstract: Methods of treating tinnitus with gaboxadol or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of tinnitus.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: January 29, 2019
    Assignee: OVID THERAPEUTICS INC.
    Inventor: Matthew During
  • Patent number: 10136669
    Abstract: A nutritional composition is provided which has an effective prophylactic and/or improving effect for various symptoms of muscle mass decrease, decreased basal metabolism, low body temperature, suppression of obesity, suppression of visceral fat accumulation, hyperglycemia, hyperlipidemia and the like in elderly people. The nutritional composition can include n-3 fatty acid and one or more of free lysine, dipeptides containing lysine, and lysine salts, wherein the content of free lysine, dipeptides containing lysine, and/or lysine salts is 0.1 g-10.0 g per 100 kcal of the composition, and the content of the total amount of n-3 fatty acid is 0.17 g-5.00 g per 100 kcal of the composition.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 27, 2018
    Assignee: AJINOMOTO CO., INC.
    Inventors: Tomoyuki Mine, Naoki Hayashi, Itaru Kon, Kazunori Saima
  • Patent number: 10137288
    Abstract: This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: November 27, 2018
    Assignee: Pop Test Abuse Deterrent Technology, LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Razvan Andrei Ene, Myron Rapkin, Rebecca O'Brien
  • Patent number: 10098856
    Abstract: A combination of dosage units for alleviating respiratory ailments and a method of alleviating respiratory ailments which uses this combination of dosage units. The dosage units comprise one or more first dosage units comprising pseudoephedrine and/or a pharmaceutically acceptable salt thereof and one or more second dosage units comprising phenylephrine and/or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: October 16, 2018
    Assignee: Sovereign Pharmaceuticals, LLC
    Inventors: Suresh Dixit, Juan Carlos Menendez, Ralph Brown
  • Patent number: 10076573
    Abstract: Biodegradable polyphosphazene polymers containing pyrrolidone side groups, and the biomedical use of such polyphosphazene polymers are disclosed.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: September 18, 2018
    Assignee: Innovo Biopolymers, LLC
    Inventors: Alexander Andrianov, Alexander Marin
  • Patent number: 10071083
    Abstract: Methods of treating tinnitus with gaboxadol or a pharmaceutically acceptable salt thereof are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of tinnitus. Methods of treating acute sensorineural hearing loss or Meniere's disease with gaboxadol or a pharmaceutically acceptable salt thereof are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of acute sensorineural hearing loss or Meniere's disease.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: September 11, 2018
    Assignee: OVID THERAPEUTICS INC
    Inventor: Matthew During
  • Patent number: 10052296
    Abstract: Formulations, methods of manufacturing, methods of stabilizing, kits, and uses as medicament are provided, for example for the treatment of pain. The formulations can comprise gabapentin optionally combined with at least one non-opioid pain drug in an aqueous carrier. The pharmaceutical formulation can have a pH of about 2.0 to about 10.0. The at least one non-opioid pain drug can be acetaminophen. The components can be included in any amount suitable for purposes of obtaining properties desirable for an injectable infusion, for example an intravenous infusion.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: August 21, 2018
    Assignee: NEVAKAR INC.
    Inventors: Varun Khurana, Vivek Yadav, Jack Martin Lipman, Tao Zhang, Iouri V. Ilitchev, Tushar Hingorani, Kumaresh Soppimath, Navneet Puri
  • Patent number: 10022446
    Abstract: A pH-responsive hybrid hydrogel, namely poly(Methacrylic acid-grafted-Ethylene Glycol) P(MAA-g-EG) cross-linked with Styrene-Butadiene-Styrene (SBS) polymer and photopolymerized by visible light. The resulting polymer turned out to have better integrities, high swelling ratios, pH-responsive and biocompatible character. Also the visible-light-induced synthesis of these pH-responsive composite wherein eosin Y is used as photoinitiator and triethanolamine is used as a co-initiator is also disclosed in the invention.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: July 17, 2018
    Assignee: KOç ÜNIVERSITESI
    Inventors: Seda Kizilel, Ozlem Cevik
  • Patent number: 10018591
    Abstract: A method for determining the levels of biomarkers, specifically, advanced glycation end products (AGEs) and oxidation products (Ops) in a biological sample such as a plasma ultrafiltrate, is used to determine a patient's risk and/or rate of developing diabetes related nephropathy. The preferred biomarkers to measure include N?-(1-carboxyethyl-lysine (CEL), methylglyoxyl-derived hydroimidazolone (MGHI) and N?-carboxymethyllysine (CML). Also provided herein is a method of diabetic care which includes determining a diabetic patient's risk of developing diabetes related kidney disease and adjusting the patient's treatment regimen to include in addition to glucose lowering agents, additional treatments such as medications that modify the renin-angiotensin system, or specialized diets with low levels of AGEs or oxidative products.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: July 10, 2018
    Assignee: PREVENTAGE HEALTHCARE, LLC
    Inventor: Paul J. Beisswenger
  • Patent number: 10010703
    Abstract: This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: July 3, 2018
    Assignee: Pop Test Abuse Deterrent Technology, LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Razvan Andrei Ene, Myron Rapkin, Rebecca O'Brien
  • Patent number: 10004710
    Abstract: A medicament to be applied as an external preparation for therapeutic treatment of a local symptom of a neuropathic disease, which contains gabapentin or pregabalin in the form of an aqueous solution.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: June 26, 2018
    Assignee: KEMPHYS LTD.
    Inventors: Koichi Shudo, Kiyoshi Sugiyama
  • Patent number: 9961932
    Abstract: The invention pertains to the use of a composition comprising per serving between 50-300 kcal; between 10 g and 35 g proteinaceous matter; and at least 2.5 microgram vitamin D, for the manufacture of a nutritional product for (a) the treatment or prevention of muscle mass decrease, (b) stimulation of muscle mass increase; or (d) stimulating muscle mass preservation, in obese or overweight adults of at least 40 years of age participating in a weight loss program. The inventors surprisingly found that nutritional supplementation with a low-caloric composition rich in protein, particularly whey protein and leucine, compared to an iso-caloric control supplement without protein, synergistically leads to preservation of muscle mass during a weight loss program involving a hypocaloric diet and a resistance exercise program in overweight/obese older adult.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: May 8, 2018
    Assignee: N.V. Nutricia
    Inventors: Peter Johan Marie Weijs, Johan De Vogel, George Verlaan, Marion Jourdan
  • Patent number: 9937138
    Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: April 10, 2018
    Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.
    Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
  • Patent number: 9926515
    Abstract: The invention is related to a contact lens care solution comprising a buffer solution, a chelating agent, a surfactant and a wetting agent, wherein the wetting agent comprises 100 parts by weight of glycerol, 0.5 to 40 parts by weight of vinylacetamide-containing polymer and 5 to 40 parts by weight of alginic acid.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: March 27, 2018
    Assignee: BENQ MATERIALS CORPORATION
    Inventors: Fan-Dan Jan, Bo-Ching Lin, Min-Chun Chung
  • Patent number: 9925159
    Abstract: D-serine is used to treat a neurological disorder, such as epilepsy, that cases seizures. A composition comprising D-serine is artificially administered to a patient in an effective amount by selectively contacting a region of the patient's brain with the composition. The region of the brain selectively contacted with the composition has cells expressing GluN3 subunit-containing triheteromeric NMDARs.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: March 27, 2018
    Assignee: The Florida State University Research Foundation, Inc.
    Inventor: Sanjay Kumar
  • Patent number: 9913808
    Abstract: The present invention relates to an injectable pharmaceutical formulation for the alleviation or reduction of joint irritation or for the reduction of worsening of existing joint inflammation, formulated for intra-articular injection comprising an active polyol ingredient, which polyol active ingredient is xylitol. Use of the intra-articular injectable formulations for the treatment of joint diseases or conditions including arthritis is described.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: March 13, 2018
    Inventor: David Segal
  • Patent number: 9901561
    Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: February 27, 2018
    Assignee: SynAgile Corporation
    Inventors: Adam Heller, Ephraim Heller, Karl Göran Westerberg, John Spiridigliozzi
  • Patent number: 9877942
    Abstract: The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: January 30, 2018
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
  • Patent number: 9878139
    Abstract: This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: January 30, 2018
    Assignee: Pop Test Abuse Deterrent Technology, LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Razvan Andrei Ene, Myron Rapkin, Rebecca O'Brien
  • Patent number: 9878138
    Abstract: This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: January 30, 2018
    Assignee: Pop Test Abuse Deterrent Technology LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Razvan Andrei Ene, Myron Rapkin, Rebecca O'Brien
  • Patent number: 9833403
    Abstract: The invention described herein is related to the preparation and usage of nanoemulsions and nanoparticles which containing biological active ingredients including cosmetic, medical and pharmaceutical active ingredients to pass skin barriers and promote cell growth with evident clinical effects. Also, the present invention contains a cosmetic formulation that can be used for skin rejuvenation, wrinkle removal, scar treatment and wounds healing.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: December 5, 2017
    Inventors: Huiwen Liu, Boke Zhang
  • Patent number: 9770421
    Abstract: The present invention relates to the use of a 1,4-benzoquinone derived compound for the treatment of a disease or condition that is associated with peroxisome proliferator activated receptor (PPAR) activity in a mammal.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 26, 2017
    Assignee: INDANIO BIOSCIENCE INC.
    Inventors: Henry Krause, Jens Tiefenbach
  • Patent number: 9763936
    Abstract: The invention relates to the use of Flibanserin for the treatment or prevention of urinary incontinence and related diseases. In a further embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment or prevention of urinary incontinence and related diseases.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: September 19, 2017
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Ramiro Castro, Angelo Ceci
  • Patent number: 9693982
    Abstract: The present invention is directed to a composition for ameliorating hypoalbuminemia containing a branched-chain amino acid(s) as an active ingredient(s), wherein the composition contains leucine and/or isoleucine as the active ingredient(s) and does not contain valine. As the above branched-chain amino acid(s), leucine and isoleucine are preferably contained. The mass ratio of leucine to isoleucine described above is preferably from 0.1 to 10. As the above branched-chain amino acid(s), either leucine or isoleucine alone may be contained. The present invention is suitably used as an infusion formulation, an oral formulation or a food or drink.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: July 4, 2017
    Assignee: OTSUKA PHARMACEUTICAL FACTORY, INC.
    Inventors: Masako Doi, Masuhiro Nishimura, Nozomi Tamura
  • Patent number: 9682025
    Abstract: The invention relates to the cosmetic use, by oral administration, of a combination of active agents including at least petroselinic acid and at least one active agent selected from among taurine, arginine, cysteine, zinc, a salt thereof, and lycopene, for improving the quality of nails, specifically the microvascularization of the nails, in particular in pre-hypertensive individuals.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: June 20, 2017
    Assignee: NUTRICOS TECHNOLOGIES
    Inventors: Yann Mahe, Carole Bru, Nathalie Piccardi, Audrey Gueniche
  • Patent number: 9675535
    Abstract: Disclosed herein is an antibacterial cleansing composition. The cleansing composition is free of triclosan and comprises lactic acid/lactate, at least one C2 to C3 alcohol, and glutamate diacetate. Lactic acid/lactate is present in the composition in an amount of about 5 weight percent (wt %) to about 15 wt %, based on the total weight of the composition. The C2 to C3 alcohol is present in an amount of about 1 wt % to about 20 wt %, based on the total weight of the composition. Glutamate diacetate is present in an amount of about 0.05 wt % to about 5 wt %. The pH of the composition is about 4 to about 5. The triclosan-free cleansing composition according to the invention has superior antibacterial activity that surpasses comparable triclosan-free formulations that do not contain glutamate diacetate.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: June 13, 2017
    Assignee: RUBBERMAID COMMERCIAL PRODUCTS/US
    Inventors: Yvan Vermeulen, Nirali Patel, John Van Cassel
  • Patent number: 9642390
    Abstract: The invention relates to a nutritional composition comprising (a) at least 18 en % of proteinaceous matter, said proteinaceous matter comprising whey; (b) at least 12 wt % of leucine, based on total proteinaceous matter; and (c) a lipid fraction comprising at least a ?-3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid for improving the muscle function in a mammal, for improving daily activity, for improving physical performance, for providing a better prognosis in terms of extended life-expectancy, for improving compliance to an anti-cancer therapy or for improving a quality of life.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: May 9, 2017
    Assignee: N.V. Nutricia
    Inventors: Klaske van Norren, Adrianus Lambertus Bertholdus van Helvoort, Joyce Faber, Robert Johan Joseph Hageman, Arjan Paul Vos
  • Patent number: 9623150
    Abstract: An injectable hydrogel, includes, in weight, in a physiologically acceptable carrier fluid: 0.01 to 5% of glycerol and 0.1 to 5% of cross-linked hyaluronic acid, or one of the salts thereof; characterized in that the hyaluronic acid or one of the salts thereof is cross-linked by the formation of covalent bonds using bifunctional or polyfunctional molecules, the injectable hydrogel being sterilized in moist heat and having viscoelastic properties such that Tan ? at a frequency of 1 Hz is less than or equal to 1.10. A method for producing the hydrogel, to a kit containing the hydrogel, as well as to the use thereof in dermatology are also described.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: April 18, 2017
    Assignee: ANTEIS S.A.
    Inventors: Samuel Gavard Molliard, Cyrille Vinchon
  • Patent number: 9499582
    Abstract: Compositions and methods utilizing thiol-containing short peptides having the sequence Cys-Lys-Met-Cys (SEQ ID NO: 1) and optionally N- and C-terminal modifications are described, for increasing carnitine level in muscle tissues, and treating or preventing diseases or disorders affecting muscle tissue.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: November 22, 2016
    Assignee: GENESISTEC LTD.
    Inventor: Josef Mograbi
  • Patent number: 9488664
    Abstract: It is to provide a tumor diagnostic agent and a tumor determination method enabling not only determination of the presence or absence of a tumor in a subject, but also determination of whether the tumor is a malignant tumor or a benign tumor, which can be used simply at low cost with reduced side effects and burden. 5-aminolevulinic acid (ALA) or its derivative, or a salt thereof is orally administered at a dose of 5 to 7 mg in terms of ALA per kg of body weight, and a urine sample 4 to 12 hours after the administration is collected. Porphyrins and creatinine in the urine sample are quantitated, and based on the value (nmol/gCre) obtained by dividing the amount of porphyrins by the amount of creatinine, a distinction among an individual without a tumor, an individual with a benign tumor, and an individual with a malignant tumor is determined. The presence or absence of a malignant tumor in a subject can be clearly determined by administering 1 to 3 mg of ALAs in terms of ALA per kg of body weight.
    Type: Grant
    Filed: January 15, 2013
    Date of Patent: November 8, 2016
    Assignee: SBI Pharmaceuticals Co., Ltd.
    Inventors: Tohru Tanaka, Kiwamu Takahashi, Motowo Nakajima, Fuminori Abe, Masahiro Ishizuka, Urara Ota
  • Patent number: 9452216
    Abstract: Provided is an agent for stabilizing acetaminophen in an aqueous composition, the agent comprising glycine. The agent further comprising at least one kind of sulfurous acid salt selected from the group consisting of sodium sulfite, potassium sulfite and potassium pyrosulfite is more effective. The stabilizing includes preventing precipitation.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: September 27, 2016
    Assignee: MARUISHI PHARMACEUTICAL CO., LTD.
    Inventors: Yutaka Itsuji, Yuko Itsuji, Mai Nomura, Hironori Nagahara
  • Patent number: 9415031
    Abstract: The present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of visual system disorders and the enhancement of the visual function.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: August 16, 2016
    Assignee: Allergan, Inc.
    Inventors: Veena Viswanath, Alan C. Foster, Yong-Xin Li, Ursula V. Staubli, Lauren M. Luhrs
  • Patent number: 9415030
    Abstract: The present invention provides for a method of treating OCD or an Obsessive-Compulsive Spectrum Disorder (OCSD), such as BDD or ADHD, using a high-dose glycine treatment.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: August 16, 2016
    Inventor: W. Louis Cleveland
  • Patent number: 9410963
    Abstract: The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to a new biomarker, its use and a method that allows it to diagnose the likelihood to resist diet induced weight gain, and/or to be susceptible to a diet induced weight gain. For example, the biomarker may be hexanoylglycine.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: August 9, 2016
    Assignee: Nestec S.A.
    Inventors: Francois-Pierre Martin, Claire L. Boulange, Ivan Montoliu Roura, Sebastiano Collino, Marc-Emmanuel Dumas, Elaine Holmes, Serge Andre Dominique Rezzi, Jeremy Nicholson, Sunil Kochhar
  • Patent number: 9393205
    Abstract: The present invention relates to a gastroretentive tablet comprising pregabalin, at least one swellable polymer, and other pharmaceutically acceptable excipients. It further relates to a process for the preparation of same.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: July 19, 2016
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Varinder Kumar, Shavej Ahmad, Romi Barat Singh
  • Patent number: 9364451
    Abstract: A combination of dosage units for alleviating respiratory ailments and a method of alleviating respiratory ailments which uses this combination of dosage units. The dosage units comprise one or more first dosage units comprising pseudoephedrine and/or a pharmaceutically acceptable salt thereof and one or more second dosage units comprising phenylephrine and/or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: June 14, 2016
    Assignee: Sovereign Pharmaceuticals, LLC
    Inventors: Suresh Dixit, Juan Carlos Menendez, Ralph Brown
  • Patent number: 9340490
    Abstract: According to the present invention, a tumor diagnostic agent which carries out early stage detection, monitoring of therapeutic effect and prognostic diagnosis of all tumors The tumor diagnostic agent of the present invention is a tumor diagnostic agent comprising ?-aminolevulinic acid represented by formula (I), a derivative thereof and a salt thereof: R2R1NCH2COCH2CH2COR3??(I) wherein R1 and R2 each independently represents hydrogen, alkyl, acyl, alkoxycarbonyl, aryl or aralkyl; and R3 represents hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, aryloxy, aralkyloxy or amino, which is used for diagnoses by measuring porphyrins in a sample collected from the inside or outside of the body after its administration.
    Type: Grant
    Filed: September 22, 2005
    Date of Patent: May 17, 2016
    Assignee: SBI PHARMACEUTICALS CO., LTD.
    Inventors: Ichiro Okura, Toshiaki Kamachi, Shunichiro Ogura, Masahiro Ishizuka, Tohru Tanaka
  • Patent number: 9295639
    Abstract: Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: March 29, 2016
    Assignee: Cumberland Pharmaceuticals Inc.
    Inventors: Leo Pavliv, Amy Dix Rock
  • Patent number: 9289426
    Abstract: The present invention provides methods of treating and enhancing efficacy of immunotherapy for a solid tumor in a subject, comprising the step of contacting the subject with a compound or composition that modulates the expression or activity of ETRB, ET-1, ICAM-1, or another protein found herein to play a role in homing of T cells to a solid tumor. The present invention also provides methods of prognosticating a solid tumor in a subject, comprising the step of measuring an expression level of a protein found herein to play a role in homing of T cells to a solid tumor, or a nucleotide molecule encoding same.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: March 22, 2016
    Assignee: UNIVERSITY OF PENNSYLVANIA
    Inventors: Ronald J Buckanovich, George Coukos, Andrea Facciabene
  • Patent number: 9283200
    Abstract: The present invention provides for methods and compositions for treating medium chain acyl-CoA dehydrogenase deficiency. It is based, at least in part, on the discovery that phenylbutyrate can serve as a substrate for medium chain acyl-CoA dehydrogenase. In non-limiting embodiments, phenylbutyrate and/or another source of phenylacetate is administered as a chaperone treatment to patients suffering from medium chain acyl-CoA dehydrogenase deficiency.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: March 15, 2016
    Inventors: Al-Walid Mohsen Mohamed, Gerard Vockley
  • Patent number: 9265831
    Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: February 23, 2016
    Assignee: Eagle Pharmaceuticals, Inc.
    Inventors: Nagesh R. Palepu, Philip Christopher Buxton
  • Patent number: 9259431
    Abstract: Long term weight loss can be achieved and maintained with a formulation of over-the-counter life-enhancing dietary supplements. One or more supplements stimulate the release of serotonin within the brain and one or more supplements stimulate the release of cholecystokinin into the bloodstream. The combined potentiating effect of these two mechanisms on satiety enables greater weight loss than that previously achieved by the individual mechanisms acting alone. A third weight loss mechanism can be achieved with the addition of phenylethylamine. Even more effective weight loss formulations can be achieved with the addition of a blue-green algae, such as aphanizomenon flos aqua, to provide a longer lasting weight loss mechanism.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: February 16, 2016
    Inventor: John V. Cappello
  • Patent number: 9254274
    Abstract: The present invention is a method of treating Tourette's Disorder (TD) using GABA ergic drugs that elevate the amount of stored presynaptic GABA and do not significantly increase GABA tone (a continuous background level of GABA signaling) in the brain. The administration of vigabatrin and/or (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride salt is expressly contemplated.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: February 9, 2016
    Assignees: Catalyst Pharmaceutical Partners, Inc., New York University, Feinstein Institute for Medical Research
    Inventors: Steven Miller, Jonathan D. Brodie, Stephen Dewey
  • Patent number: 9155719
    Abstract: The invention relates to a medicament, the active principle of which is a leucine and, for example, a N-ACETYL-DL-LEUCINE. It can be applied to the prevention and/or treatment of eye diseases or disorders and especially of hereditary dystrophies of the retina, glaucomatous neuropathy, glaucoma, macular degeneration, myopia, presbyopia, hypermetropia, astigmatism, all the ophtalmologic diseases or disorders inducing a decrease of visual function and/or age-related physiological vision decline.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: October 13, 2015
    Inventor: Raouf Rekik
  • Patent number: 9119416
    Abstract: A muscle fatigue remedy that for persons with the symptoms of muscle pain attributed to strenuous exercise, lassitude in the arms and legs attributed to acute exercise, lower back pain and stiffness in the shoulder attributed to taking of a certain posture over a prolonged period of time, etc., relieves the symptoms and allows them to have a fulfilling life. There is provided a muscle fatigue remedy containing alanylglutamine or its salt as an active ingredient.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: September 1, 2015
    Assignee: Kyowa Hakko Bio Co., Ltd.
    Inventors: Miho Komatsu, Koji Morishita, Shin-ichi Hashimoto
  • Patent number: 9084431
    Abstract: A process for preparing a dry substantially pure and/or technical carnitine powder or granulate, from a substantially unpurified starting material containing a carnitine compound.
    Type: Grant
    Filed: July 5, 2006
    Date of Patent: July 21, 2015
    Assignee: LONZA LTD.
    Inventor: Max Baumgartner
  • Patent number: 9066868
    Abstract: Subject of the invention is a method for the production of a carnitine granulate, which includes the steps of (a) providing an aqueous solution comprising at least 65% (w/w) carnitine, (b) providing a particulate carrier comprising silica, the carrier having an average particle size of more than 150 ?m, and (c) mixing the aqueous solution and the carrier. Another subject of the invention is a carnitine granulate.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: June 30, 2015
    Assignee: LONZA LTD.
    Inventor: Thomas Buchner